Navellier & Associates Inc Intellia Therapeutics, Inc. Transaction History

Navellier & Associates Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 29, 2022	SELL	$58.27 - $118.99 $205,809 - $420,272	-3,532 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $3,627 - $4,980	-36 Reduced 1.01%	3,532 $418,000
Q3 2021 Oct 28, 2021	SELL	$132.37 - $176.78 $18,267 - $24,395	-138 Reduced 3.72%	3,568 $479,000
Q2 2021 Aug 09, 2021	SELL	$60.88 - $161.91 $1,826 - $4,857	-30 Reduced 0.8%	3,706 $600,000
Q4 2020 Feb 05, 2021	BUY	$18.83 - $63.53 $70,348 - $237,348	3,736 New	3,736 $203,000

336

91M

728K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $813M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Navellier & Associates Inc with notifications on news.